{"id":36859,"date":"2026-04-03T09:52:00","date_gmt":"2026-04-03T13:52:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=36859"},"modified":"2026-03-08T14:25:52","modified_gmt":"2026-03-08T18:25:52","slug":"two-roads-to-generic-drug-profits-the-us-niche-strategy-vs-indias-mass-market-model","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/two-roads-to-generic-drug-profits-the-us-niche-strategy-vs-indias-mass-market-model\/","title":{"rendered":"Two Roads to Generic Drug Profits: The US Niche Strategy vs. India’s Mass Market Model"},"content":{"rendered":"\n

A deep-dive into the economics, IP strategy, and competitive dynamics shaping two divergent paths for branded generic pharmaceutical companies<\/em><\/p>\n\n\n\n

The Fork in the Road<\/h1>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Every pharmaceutical executive who runs a generic drug operation faces the same binary choice that looks simple on the surface and turns out to be anything but. On one path lies the United States: a market of 330 million people, sky-high drug prices, ferocious patent litigation, a regulatory agency that requires years and tens of millions of dollars just to get a product approved, and the promise of extraordinary margins if you can find and defend a niche. On the other path lies India: a market of 1.4 billion people, among the world’s lowest per-unit drug prices, a regulatory environment that generic manufacturers know how to work, and a competitive landscape where brand equity, doctor relationships, and field sales armies determine who wins.<\/p>\n\n\n\n

These two models are not simply geographical variations on the same theme. They represent fundamentally different theories of how to build a profitable pharmaceutical business, how to deploy intellectual property, how to price products, how to sell them, and ultimately how to create value for shareholders. A company that masters one model does not automatically succeed with the other. The skills, capital requirements, regulatory knowledge, and competitive tactics are different enough that several Indian pharmaceutical companies have spent billions of dollars trying to crack the US niche market and achieved mixed results, while Western companies that entered India expecting their brand power to translate often found themselves outmaneuvered by local players who understood the economics of high-volume, low-margin prescription medicine.<\/p>\n\n\n\n

This article examines both models in depth: where each generates returns, what the IP strategy looks like in each context, and whether the companies trying to run both simultaneously are building durable competitive advantages or spreading themselves too thin. The analysis draws on patent filing data, publicly available financial disclosures, regulatory records, and the kind of patent landscape intelligence that platforms like DrugPatentWatch make accessible to analysts and executives who need to understand the competitive clock ticking on any molecule they are considering.<\/p>\n\n\n\n

The financial stakes are not academic. The global branded generics market was valued at approximately $408 billion in 2022 and is projected to reach $649 billion by 2030, according to Grand View Research. [1] How that revenue distributes between the US niche model and the India mass market model, and which companies capture the most durable share of it, depends on decisions being made right now in boardrooms in Mumbai, Hyderabad, New York, and New Jersey.<\/p>\n\n\n\n

What “Branded Generic” Actually Means<\/h1>\n\n\n\n

The term “branded generic” creates confusion because it means different things in different markets, and the confusion matters for anyone trying to analyze the business models correctly.<\/p>\n\n\n\n

Defining the Category<\/h2>\n\n\n\n

In the United States, the term most often refers to a drug that is chemically equivalent to an off-patent reference listed drug but is sold under a proprietary brand name rather than its generic International Nonproprietary Name (INN). This can happen through a 505(b)(2) regulatory pathway that allows reformulation, a new delivery mechanism, or a new indication to justify a brand premium. It can also refer to authorized generics: products that an innovator company licenses to a generic subsidiary or partner to compete with its own brand once the exclusivity period ends.<\/p>\n\n\n\n

In India, the meaning is both simpler and more commercially central to the entire pharmaceutical industry. Nearly every drug sold in India through prescription channels carries a brand name, even if the molecule itself has been off-patent for decades. A tablet of metformin in the United States is likely sold as a commodity generic with no brand, competing purely on price and pharmacy substitution. In India, the same molecule is sold under dozens of competing brand names by different manufacturers, each trying to build physician preference, patient loyalty, and distributor relationships. Brands like Glycomet (Sun Pharma), Glucophage (Abbott), and Obimet (Glenmark) compete in the same segment not through price alone but through brand recognition, sales force coverage, and the trust accumulated over years of consistent quality and supply.<\/p>\n\n\n\n

This definitional divergence is not just semantic. It shapes the entire competitive strategy. In the US, the branded generic manufacturer must justify its price premium through regulatory protection, reformulation, or specialty channel access. In India, the branded generic manufacturer must justify its price premium through physician preference, which is built through personal selling, medical education, and the intangible currency of trust in a market where quality variation between manufacturers is real and feared.<\/p>\n\n\n\n

The Commodity Generic Contrast<\/h2>\n\n\n\n

Neither model should be confused with the commodity generic model that dominates US pharmacy chains and mail-order operations. Companies like Teva, Mylan (now Viatris), and Amneal compete in that space by driving costs to their absolute floor, filing first-to-file Paragraph IV challenges to capture 180-day exclusivity windows, and running enormous manufacturing operations that generate scale efficiencies measured in cents per tablet. The margins are thin, the competition is brutal, and the business is entirely driven by manufacturing cost and regulatory speed. Neither the US niche model nor the India branded generic model operates in this space, and that distinction matters when analyzing the financial profiles of companies that claim to compete in branded generics.<\/p>\n\n\n\n

The US Niche Market Model: How It Works<\/h1>\n\n\n\n

The US pharmaceutical niche market is built on a simple proposition: if you can find a patient population small enough that large generic competitors ignore it, but real enough that payers will cover treatment, you can charge prices that generate extraordinary margins on relatively low volumes. The regulatory, legal, and commercial infrastructure of the United States creates multiple mechanisms that allow companies to build and defend those positions.<\/p>\n\n\n\n

The 505(b)(2) Pathway: The Niche Builder’s Best Friend<\/h2>\n\n\n\n

The 505(b)(2) New Drug Application pathway allows a company to seek FDA approval for a drug product by relying partly on published literature or the FDA’s prior findings of safety and effectiveness for a previously approved drug. This is the regulatory tool that separates niche branded generics from true commodity generics. A company can take a well-understood molecule, reformulate it into an extended-release capsule, a transdermal patch, or an intravenous formulation, and file a 505(b)(2) application. If approved, the product gets a new approved drug application, potential new exclusivity periods, and the legal right to be sold under a brand name at a price point that reflects the new formulation’s clinical value.<\/p>\n\n\n\n

The FDA granted 505(b)(2) approvals for 64 products in fiscal year 2022, according to FDA records [2], and many of those were for reformulations or new delivery systems of existing molecules. Each one of those approvals is potentially the foundation for a niche branded generic position. The key is identifying molecules where the reformulation provides genuine clinical benefit — reduced dosing frequency, improved tolerability, more reliable absorption — and then building the data package and commercial argument that supports a price premium.<\/p>\n\n\n\n

Orphan Drugs and the Exclusivity Scaffold<\/h2>\n\n\n\n

The Orphan Drug Act of 1983 created one of the most durable sources of niche market protection in the US pharmaceutical industry. Drugs that receive Orphan Drug Designation for conditions affecting fewer than 200,000 Americans get seven years of market exclusivity after approval, tax credits for clinical development costs, and expedited regulatory review. For a company focused on the US niche model, orphan indications are among the most valuable IP assets available.<\/p>\n\n\n\n

The commercial logic is compelling. A drug for a 50,000-patient population with no approved treatment can command annual treatment costs of $50,000 to $500,000 per patient in the current US market. Even at those prices, the therapy is often cost-effective by quality-adjusted life year (QALY) standards because the disease burden is so severe. Payers grumble but typically cover the cost because denying coverage for a rare disease with no alternative invites regulatory and public relations consequences they prefer to avoid.<\/p>\n\n\n\n

Horizon Therapeutics built its business almost entirely on this logic before AstraZeneca acquired the company for $27.8 billion in 2023 [3]. Horizon’s portfolio consisted of drugs for rare inflammatory and autoimmune conditions, several of them reformulations or repurposings of previously approved molecules, all priced at levels that generated substantial gross margins. The company did not discover new molecular entities in the traditional sense. It found molecules with known pharmacology, identified rare indications where those molecules could work, obtained orphan designation, ran appropriately sized clinical trials, and built specialty commercial infrastructure to reach the small patient populations and prescribing specialists involved.<\/p>\n\n\n\n

Specialty Pharma and the Consolidation Playbook<\/h2>\n\n\n\n

The specialty pharma model that flourished in the 2000s and 2010s took the niche logic to its extreme. Companies like Shire, NPS Pharmaceuticals, BioMarin, and the now-notorious Valeant Pharmaceuticals identified that niche pharmaceutical assets were systematically undervalued by large companies that needed blockbuster revenue to move the needle. They acquired those assets aggressively, raised prices, cut research spending, and operated lean commercial organizations that were highly efficient at extracting value from defined patient populations.<\/p>\n\n\n\n

Valeant’s model eventually collapsed under the weight of its own excesses and an unsustainable acquisition-driven debt load, but the core insight that drove its early success was sound: small-patient-population drugs in the US market can generate exceptional returns if managed with operational discipline. The companies that operated more sustainably — Horizon, Ultragenyx, Alexion (before AstraZeneca acquisition) — proved that the niche model can generate durable value when the scientific foundation is real and the pricing is defensible.<\/p>\n\n\n\n

The Dermatology Niche<\/h4>\n\n\n\n

Dermatology has been one of the most consistently productive niche markets for branded generics in the US. The combination of insurance coverage, a concentrated prescriber base of approximately 12,000 practicing dermatologists, strong patient preference for branded products, and the availability of reformulation opportunities around well-understood molecules has made dermatology an attractive segment for companies that can navigate the FDA process and build specialty sales forces. Companies like Noven, Stiefel (acquired by GSK), and Foamix (now acquired by Vyne Therapeutics) built significant businesses around reformulated dermatology products that would have been commodity generics if sold in their original forms.<\/p>\n\n\n\n

Patent Strategy in US Niche Markets<\/h2>\n\n\n\n

The IP strategy for a US niche branded generic player is more sophisticated than simply filing a patent and waiting for it to expire. Effective niche players build what patent attorneys call a “patent thicket” or “layered IP” strategy: a series of overlapping patents covering the composition of matter, the formulation, the manufacturing process, the method of treatment, and the dosing regimen, each with a different expiration date that extends the total period of exclusivity beyond any single patent.<\/p>\n\n\n\n

Consider a hypothetical extended-release formulation of an established pain medication. The original compound patent may have expired decades ago. But a novel extended-release polymer matrix, filed as a new composition patent, might have a 2028 expiration. A method patent covering the specific dosing frequency found to reduce gastrointestinal side effects might expire in 2031. A formulation patent covering the specific particle size distribution and its relationship to bioavailability might expire in 2033. None of these patents individually is worth much. Together, they create a legal barrier to generic entry that a would-be competitor must defeat in litigation before launching, typically through Paragraph IV certification and a patent challenge.<\/p>\n\n\n\n

Tracking this kind of layered patent landscape requires systematic intelligence. DrugPatentWatch is one of the primary tools that pharmaceutical analysts, competitive intelligence teams, and patent attorneys use to map the patent status of specific products, identify which patents are listed in the FDA’s Orange Book as protecting a given product, and model the competitive timeline for generic entry. When a company is evaluating whether to acquire a niche branded generic asset, the patent timeline is one of the first analyses required. DrugPatentWatch’s database allows teams to pull the complete patent coverage for a product, see when each patent expires, and identify whether any competitors have already filed Paragraph IV challenges that could accelerate generic entry.<\/p>\n\n\n\n

“The period during which a drug faces no generic competition accounts for approximately 90% of total brand revenue over the product’s lifecycle” — IMS Health \/ IQVIA analysis of US pharmaceutical product revenue cycles [4]<\/em><\/p>\n\n\n\n

PBMs and Specialty Pharmacy: The Gatekeepers<\/h2>\n\n\n\n

In the US, a niche branded generic does not simply sell itself through standard retail pharmacy channels. The specialty pharmacy ecosystem — a network of pharmacies accredited to handle complex therapies, tied to pharmaceutical manufacturers through hub services, prior authorization support, and patient assistance programs — is both an enabler and a cost center for niche players. Pharmacy Benefit Managers (PBMs) like CVS Caremark, Express Scripts (now Cigna), and OptumRx control formulary placement for the majority of commercially insured lives in the United States. A branded generic that does not get favorable formulary placement faces a step therapy requirement that means physicians must prescribe a cheaper alternative first before the insurer will cover the branded product.<\/p>\n\n\n\n

Managing PBM relationships is a core competency for US niche branded generic companies. It requires rebate negotiations, health economics data demonstrating cost-effectiveness, and sometimes patient advocacy relationships that can put public pressure on payers to cover life-saving treatments. Companies that underestimate this challenge often see commercial launches fail not because the product lacks clinical merit but because the payer access strategy was underfunded or poorly designed.<\/p>\n\n\n\n

India’s Mass Market Model: Volume, Brand, and the Field Force<\/h1>\n\n\n\n

India’s pharmaceutical market operates by entirely different rules. With approximately 1.4 billion people, per capita income that remains a fraction of US levels, and a public healthcare system that provides limited coverage for private prescription drugs, the Indian market rewards companies that can achieve enormous prescription volume at price points that Indian patients and their families can actually pay. The economics are the mirror image of the US niche model: low margin per unit, high volume, with returns driven by scale, brand loyalty, and the distribution machine.<\/p>\n\n\n\n

The Structure of India’s Branded Generic Market<\/h2>\n\n\n\n

India’s pharmaceutical market is enormous by volume and relatively modest by value. The domestic formulations market was worth approximately $21 billion in 2023 according to IQVIA India, [5] compared to a US branded prescription market worth more than $600 billion in the same year. But the number of prescriptions filled in India dwarfs what happens in the US. Anti-infectives, cardiovascular drugs, gastrointestinal products, and vitamins and nutritional supplements together account for the majority of prescription volume. These are largely mature therapeutic categories with well-understood molecules that have been off-patent for years or decades.<\/p>\n\n\n\n

The defining characteristic of the Indian branded generic market is that molecular differentiation matters less than brand differentiation. A physician in Ahmedabad choosing between twenty different brands of atorvastatin is not making a decision based on patent status, formulation technology, or regulatory exclusivity. The decision is driven by which brand’s medical representative visited most recently, which company provided a recent continuing medical education program, which brand has a reputation for consistent quality, and sometimes — though this is now subject to stringent Medical Council of India and National Medical Commission regulations — which company provides the most attractive non-monetary incentives.<\/p>\n\n\n\n

The Field Force: India’s Pharmaceutical Sales Engine<\/h2>\n\n\n\n

No aspect of Indian pharmaceutical commercial operations is more central to the branded generic model than the medical representative, or MR. India has approximately 600,000 to 700,000 pharmaceutical sales representatives, according to industry estimates — one of the largest field sales armies in any industry in any country. [6] These representatives visit physicians, sometimes daily for the most sought-after prescribers, to promote their company’s branded generics. They carry product samples, scientific literature, promotional materials, and in many cases gifts that have become the subject of ongoing regulatory and ethical debate.<\/p>\n\n\n\n

The MR system creates significant barriers to entry for companies without an established field force. Building a pan-India network of 2,000 to 5,000 representatives — which is what a mid-size domestic pharmaceutical company needs to compete across major metros and tier-two cities — takes years and substantial investment. The cost of a representative in terms of salary, incentives, travel, and supervision runs to approximately 600,000 to 900,000 rupees per year in the current market. A 3,000-person field force costs roughly $30 to $40 million annually at current exchange rates before any promotional material, sample, or event expenditure.<\/p>\n\n\n\n

Sun Pharmaceutical Industries maintains one of the largest field forces in India, covering more than 17 different therapeutic divisions. Cipla, Dr. Reddy’s Laboratories, Zydus Lifesciences (formerly Cadila Healthcare), and Torrent Pharmaceuticals each operate multi-thousand-person field forces segmented by therapeutic area. Lupin, which has pursued an aggressive US strategy, still derives a substantial portion of its revenue from Indian branded generics and maintains extensive field coverage. The field force is not just a sales mechanism — it is the primary market intelligence network that tells pharmaceutical companies which therapeutic areas are growing, which competitors are gaining traction, and which physicians are the most influential prescribers in any given geography.<\/p>\n\n\n\n

Pricing Dynamics: The DPCO Constraint<\/h2>\n\n\n\n

The Drug Price Control Order (DPCO), most recently revised in 2013 with subsequent amendments, imposes price caps on drugs included in the National List of Essential Medicines (NLEM). As of 2022, the NLEM covers 384 formulations, and manufacturers of NLEM drugs must keep their prices within the ceiling set by the National Pharmaceutical Pricing Authority (NPPA). [7]<\/p>\n\n\n\n

Price control creates a genuine strategic tension for Indian branded generic companies. On one hand, price-controlled categories like essential antibiotics, cardiovascular drugs, and anti-diabetics are among the highest-volume therapeutic areas in India. Any company not present in these categories is missing a large portion of the market. On the other hand, price controls compress margins precisely in the categories where volume is highest, pushing companies to generate returns through volume alone. The practical consequence is that Indian branded generic companies tend to be extraordinarily focused on cost-per-tablet, manufacturing efficiency, and raw material sourcing in a way that US niche players simply do not need to be.<\/p>\n\n\n\n

The non-NLEM segments — specialty, lifestyle, and chronic disease management drugs outside the essential medicines list — offer higher margins and have historically been where premium Indian branded generic players have tried to build differentiated positions. Dermatology, psychiatry, certain pain management categories, and vitamins and supplements have operated largely outside price controls and have attracted significant brand-building investment. Sun Pharma’s position in dermatology and specialty segments in India reflects this logic: the company built premium branded positions in categories where price controls were absent and physician preference could command a margin premium.<\/p>\n\n\n\n

Therapeutic Concentration: The India Emphasis<\/h2>\n\n\n\n

India’s disease burden shapes the branded generic market’s therapeutic geography in ways that differ substantially from the US. Anti-infectives — antibiotics, antifungals, antiparasitic drugs — represent a much larger proportion of total prescription volume in India than in the US, reflecting higher rates of infectious disease and substantial antibiotic prescribing patterns that would be considered problematic by US clinical standards. Cardiovascular medicines reflect India’s growing burden of hypertension, coronary artery disease, and dyslipidemia. Gastrointestinal products, including proton pump inhibitors, antispasmodics, and probiotic formulations, are major revenue contributors.<\/p>\n\n\n\n

The chronic disease categories — diabetes, hypertension, asthma — have been the fastest-growing segments of India’s branded generic market over the past decade, reflecting both epidemiological change and improved diagnostic detection. These categories present a specific commercial challenge: chronic disease patients need their drugs reliably every month, which drives demand for consistent supply chains and brand trust in a way that acute therapy purchases do not. A patient who starts a brand of metformin and finds it works without side effects will likely continue that brand for years, creating the kind of customer loyalty that Indian branded generic companies understand and invest in building.<\/p>\n\n\n\n

The Top Players and Their Strategies<\/h2>\n\n\n\n

Sun Pharmaceutical Industries is the dominant force in Indian branded generics by revenue and market capitalization, with a domestic formulations business worth approximately $1.5 billion annually. Sun built its domestic franchise through a combination of acquisitions (including the controversial Ranbaxy acquisition in 2015), organic brand launches, and specialty segment leadership. The company’s strength in psychiatry and dermatology in India mirrors its US ambitions in those same categories, creating an interesting parallel franchise that shares scientific and commercial capabilities across geographies.<\/p>\n\n\n\n

Cipla’s domestic branded generic business is built on respiratory medicine, where the company’s scientific heritage in inhaler formulation technology creates genuine product differentiation. Cipla’s Seroflo, Foracort, and Asthalin brands are among the most recognized in Indian respiratory medicine and command price premiums that reflect real clinical performance differences from generic alternatives. Cipla’s domestic success in respiratory has also informed its US respiratory strategy, where the company has pursued FDA approval for generic and branded versions of inhaled corticosteroids and long-acting beta agonists.<\/p>\n\n\n\n

Torrent Pharmaceuticals represents a different model: a company that has built strong branded generic positions in India’s cardiovascular and central nervous system categories with a more limited international footprint than Sun or Dr. Reddy’s. Torrent’s domestic market focus has allowed it to invest deeply in physician relationships and field force quality in specific therapeutic areas rather than spreading resources across a global generic manufacturing platform.<\/p>\n\n\n\n

The Economic Calculus: Margin vs. Scale<\/h1>\n\n\n\n

The fundamental financial difference between the two models can be illustrated by a single comparison. A US niche branded generic product for a specialty indication — an orphan designation drug, or a 505(b)(2) reformulation sold through specialty pharmacy — might generate revenue of $50,000 per patient per year at a gross margin of 70 to 80 percent. A high-volume Indian branded generic in a cardiovascular category might generate revenue of $15 to $25 per patient per year at a gross margin of 40 to 55 percent. The US product needs 2,000 patients to generate $100 million in revenue. The Indian product needs 5 to 7 million patients.<\/p>\n\n\n\n

Revenue Per Prescription: The Starkest Contrast<\/h2>\n\n\n\n

In the United States, the average branded drug prescription generates revenue of approximately $350 to $500, with specialty drugs generating multiples of that figure. Even a commodity generic prescription in the US generates $30 to $50 in revenue for the manufacturer after pharmacy and PBM deductions. In India, the average prescription in a branded generic context generates approximately $2 to $8 in manufacturer revenue, depending on the therapeutic category and the specific products involved. The revenue-per-prescription gap between the US and India is not a 10x or 20x difference — it is a 50x to 200x difference at the extreme ends of the distribution.<\/p>\n\n\n\n

This arithmetic shapes everything else about the two business models. US niche players can afford to spend $20,000 to $50,000 per physician target on medical education and clinical trial data because the lifetime value of a converted prescriber is enormous. Indian branded generic companies spend a few thousand rupees per physician per year because the revenue generated per prescription does not support higher per-physician investments. The US niche player runs a high-touch, low-volume commercial model. The Indian branded generic company runs a high-volume, low-touch commercial model at scale.<\/p>\n\n\n\n

R&D Investment: The Different Questions<\/h2>\n\n\n\n

The R&D investment profile also differs sharply. A US niche player pursuing a 505(b)(2) strategy needs to fund bioequivalence studies, pharmacokinetic profiling, potentially a Phase 2 or Phase 3 efficacy study to support a new indication, and the full FDA review process including potential Advisory Committee presentations. Total development costs for a 505(b)(2) product typically run $10 million to $75 million, depending on the clinical evidence required. That is not the $1 billion to $2.5 billion required for a new molecular entity, but it is still a substantial investment that requires a confident revenue forecast to justify.<\/p>\n\n\n\n

Indian branded generic companies, by contrast, invest relatively little in regulatory approval because CDSCO (the Central Drugs Standard Control Organisation) requires generic product approval documentation that, while not trivial, is less demanding than FDA requirements. The R&D investment in India goes instead into process chemistry improvements, stability studies for new formulations, and the kind of incremental pharmaceutical development that creates product differentiation within the regulatory framework. Companies like Lupin and Dr. Reddy’s that pursue both US and India strategies must manage two entirely different R&D investment philosophies simultaneously, and the capital allocation discipline required to do that without starving either franchise is genuinely difficult.<\/p>\n\n\n\n

Manufacturing Economics: Different Drivers<\/h2>\n\n\n\n

Indian pharmaceutical manufacturers operate some of the world’s most cost-efficient production facilities. A fully loaded manufacturing cost for a standard oral solid dosage form produced at scale in India — tablets, capsules, the basic formulations that drive the domestic branded generic market — runs at a fraction of comparable US or European production costs. Land, labor, utilities, and API sourcing from domestic chemical manufacturers create a cost structure that allowed Indian companies to dominate the US commodity generic market and that sustains the Indian domestic branded generic market at its characteristically low price points.<\/p>\n\n\n\n

US niche players operate with a different manufacturing logic. Many do not own their own manufacturing facilities at all, preferring to outsource production to contract manufacturers and focus capital on regulatory, clinical, and commercial activities. For a niche product with annual volume of 100,000 to 500,000 units, the economics of dedicated manufacturing rarely work. The unit cost of outsourced production for a low-volume specialty product can be 10 to 20 times the unit cost of high-volume Indian commodity generic production, but that does not matter when the product is priced at $500 per unit rather than $0.05.<\/p>\n\n\n\n

Indian Companies Enter the US Niche Space<\/h1>\n\n\n\n

The attempt by Indian pharmaceutical companies to translate their domestic branded generic success into the US market is one of the most closely watched strategic experiments in global pharmaceuticals. Several of India’s largest companies have made significant investments in the US niche market, with results ranging from impressive to expensive.<\/p>\n\n\n\n

Sun Pharma’s Specialty Pivot<\/h2>\n\n\n\n

Sun Pharmaceutical Industries has made the most systematic attempt among Indian companies to build a genuine US specialty pharmaceutical business. The Ranbaxy acquisition in 2015 was partly motivated by the US business it brought, but Sun’s real US niche ambition crystallized around its specialty and branded product investments. The company acquired Dusa Pharmaceuticals (photodynamic therapy for actinic keratosis), InSite Vision (ophthalmology), and most significantly, the rights to ilumya (tildrakizumab) for plaque psoriasis, which it launched in the US in 2018.<\/p>\n\n\n\n

Ilumya is a biologic, not a branded generic in the traditional sense, but Sun’s investment in it reflects the same strategic logic: find a niche indication with defined patient population, build the clinical data package required by FDA, and extract premium pricing through specialty commercial infrastructure. The psoriasis biologics market in the US is intensely competitive, with Humira, Cosentyx, Skyrizi, and Tremfya all competing for market share. Sun’s experience with ilumya demonstrated both the opportunity and the difficulty: the drug achieved modest market penetration but never achieved the commercial velocity that would justify its development and launch investment, ultimately generating revenue well below analyst expectations.<\/p>\n\n\n\n

Dr. Reddy’s Laboratories: The Cautious Approach<\/h2>\n\n\n\n

Dr. Reddy’s Laboratories has pursued a more measured US niche strategy, focusing on complex generics and limited competition products rather than branded specialty pharmaceuticals. The company’s PSAI (Pharmaceutical Services and Active Ingredients) division and its generics business have generated consistent US revenue, but Dr. Reddy’s has deliberately avoided the heavy investment in specialty commercial infrastructure that a true US niche branded generic strategy requires. The company’s branded presence in India remains strong, particularly in gastroenterology, cardiovascular, and dermatology, and senior management has indicated a preference for building US generic complexity rather than US brand investment.<\/p>\n\n\n\n

This approach is financially conservative but strategically limiting. The complex generics market in the US — injectable formulations, modified-release oral solids, transdermal systems — does offer better margins than commodity oral solids and is less susceptible to immediate multi-player competition after launch. But it is not the same as a true niche branded position, and it does not generate the kind of pricing power that makes the US niche model so attractive to companies that can access it.<\/p>\n\n\n\n

Glenmark’s Specialty Ambitions and the Ichnos Spin-Out<\/h2>\n\n\n\n

Glenmark Pharmaceuticals has had perhaps the most complex US niche strategy among major Indian companies. The company invested heavily in building an innovative drug discovery capability, spinning it out as Ichnos Sciences in 2019, with the goal of developing novel biologics and small molecules for oncology and inflammatory diseases that could be commercialized in the US at premium prices. [8] Glenmark retained its generic US business and its strong Indian branded generic franchise while Ichnos pursued the innovative pipeline.<\/p>\n\n\n\n

The Ichnos strategy reflects a recognition that competing in US specialty pharmaceuticals at the highest value point requires genuine innovation, not reformulation. A molecule that is truly novel, with first-in-class or best-in-class potential, can command prices that reformulated or repurposed molecules cannot. But developing truly novel molecules requires Phase 1, Phase 2, and Phase 3 clinical investment at a scale that most Indian pharmaceutical companies have historically not been able to sustain. Ichnos has advanced several molecules into clinical trials, but the commercial validation of Glenmark’s innovative strategy remains in the future.<\/p>\n\n\n\n

The Regulatory Cost of Entry<\/h2>\n\n\n\n

One structural barrier that Indian companies face in the US niche market deserves specific attention: the cost and complexity of FDA compliance for manufacturing facilities. The FDA has issued import alerts against facilities operated by several major Indian pharmaceutical manufacturers, including plants operated by Ranbaxy (before its Daiichi Sankyo and then Sun acquisition), Wockhardt, Cipla, and others. Import alerts effectively bar products made at those facilities from the US market, creating supply disruptions that can be devastating for commercial launches.<\/p>\n\n\n\n

The root cause of most of these import alerts has been inadequate data integrity: falsified test results, incomplete laboratory records, and quality systems that did not meet FDA’s Current Good Manufacturing Practice (cGMP) standards. The pattern is not a coincidence — it reflects the fact that Indian manufacturing culture historically optimized for cost efficiency and volume throughput in ways that were sometimes incompatible with the documentation discipline that the FDA requires. Companies that want to compete in the US niche market must invest in quality systems that are as robust as the clinical and commercial infrastructure, and that investment is both expensive and ongoing.<\/p>\n\n\n\n

Western Companies in India’s Branded Generic Market<\/h1>\n\n\n\n

The traffic between these two models runs in both directions. Several large Western pharmaceutical companies have built significant branded generic businesses in India, attracted by the market’s growth trajectory and the potential to monetize off-patent molecules in a high-volume environment. Their experiences illuminate the specific challenges of the India mass market model from an outsider perspective.<\/p>\n\n\n\n

Abbott’s Established Pharmaceuticals: The Case for Local Commitment<\/h2>\n\n\n\n

Abbott Laboratories’ decision to create an Established Pharmaceuticals Division focused on emerging markets, including India, was one of the more prescient strategic moves in Western pharmaceutical history. When Abbott acquired Piramal Healthcare’s domestic branded generic business in 2010 for $3.72 billion [9], critics questioned whether the price made sense for a portfolio of largely off-patent drugs in a price-controlled market. A decade later, Abbott’s India branded generic business has grown steadily and generates consistent revenue from a portfolio of well-established brands in women’s health, gastroenterology, vitamins, and cardiovascular medicine.<\/p>\n\n\n\n

Abbott’s success in India rested on two decisions that other Western entrants often got wrong. First, the company committed to maintaining and investing in the local field force it acquired, rather than trying to rationalize it to Western commercial efficiency standards. The Indian field force model requires more representatives per prescriber than a Western pharmaceutical company would typically deploy, and the expectation of frequent, in-person visits to physicians is a feature of the market, not an inefficiency to be eliminated. Second, Abbott allowed the acquired brands to continue operating under their established Indian identities rather than trying to convert everything to global Abbott branding, which would have sacrificed the physician trust accumulated by the original brands over years.<\/p>\n\n\n\n

Pfizer and the Consumer Healthcare Pivot<\/h2>\n\n\n\n

Pfizer’s approach to India has been more fragmented. The company has a prescription pharmaceuticals business in India and a consumer healthcare business, but it has not made the kind of large-scale commitment to Indian branded generics that Abbott did. Pfizer’s Indian prescription pharmaceutical business competes in antibiotics (Pfizerpen, Amoxil), cardiovascular (Norvasc), and specialist segments, but it does not have the scale of field coverage or the breadth of domestic brand portfolio that the largest Indian players have built.<\/p>\n\n\n\n

The lesson from comparing Abbott and Pfizer in India is about strategic clarity: companies that commit to the Indian branded generic model with dedicated capital, local operational autonomy, and a willingness to operate by local commercial norms tend to outperform companies that treat India as an extension of their global pharmaceutical business and expect Western operating models to translate.<\/p>\n\n\n\n

The European Approach: Sanofi and Servier<\/h2>\n\n\n\n

Sanofi has a long history in India through its insulin and diabetes portfolio, and the Lantus brand has genuine clinical differentiation in that market. Servier, the French specialty pharmaceutical company, has built a meaningful branded presence in cardiovascular medicine through its ramipril-based products. Both companies benefit from therapeutic areas where their global products have genuine clinical advantages that can support brand premiums in the Indian market. The lesson here is that Western companies can compete effectively in India when they have proprietary products with real clinical differentiation — rather than simply trying to put Western brand premiums on commodity molecules that Indian manufacturers produce more cheaply.<\/p>\n\n\n\n

IP Strategy: The Critical Differentiator Between Models<\/h1>\n\n\n\n

Intellectual property strategy is where the two models diverge most sharply, and where the analytical tools available to practitioners create the greatest competitive advantage.<\/p>\n\n\n\n

Patent Cliffs and the US Niche Opportunity<\/h2>\n\n\n\n

The United States experiences patent cliffs — the sudden loss of exclusivity for high-revenue branded drugs — on a regular schedule that creates predictable business development opportunities. When a major branded drug loses exclusivity, commodity generic manufacturers race to file ANDAs and capture the rapidly eroding brand market. But not every patient on that brand switches to the commodity generic. Some continue with the brand or are switched by their physicians to a newer branded product in the same class. The prescribers who continue writing for patients in that therapeutic category after the cliff are potential targets for a niche branded generic that offers some incremental clinical benefit — a better tolerability profile, a more convenient dosing schedule, a specialized formulation for patients who cannot swallow standard tablets.<\/p>\n\n\n\n

Identifying these opportunities requires systematic patent landscape analysis. Which blockbusters are coming off-patent in the next three to five years? Which of those have patient populations with unmet needs that a reformulation or repurposing could address? Which patents covering those molecules or their therapeutic uses are still in force and might provide the basis for a 505(b)(2) application that could generate new exclusivity? These are the questions that business development teams at niche pharmaceutical companies work through systematically, and patent intelligence platforms like DrugPatentWatch provide the foundational data for that analysis.<\/p>\n\n\n\n

DrugPatentWatch maintains comprehensive databases of Orange Book patent listings, patent expiration dates, Paragraph IV certification filings, and regulatory exclusivity periods for US approved drugs. A team evaluating whether to invest in a new niche branded generic asset will typically start with a DrugPatentWatch analysis to understand the patent landscape, identify whether any current patents create freedom-to-operate concerns, and map the timeline to generic competition that will eventually erode the branded position they are considering building.<\/p>\n\n\n\n

Paragraph IV Litigation: Defense and Offense<\/h2>\n\n\n\n

Paragraph IV certification is the mechanism by which a generic manufacturer challenges the validity or applicability of patents listed in the Orange Book for a branded reference product. When a generic company files a Paragraph IV certification, it must notify the patent holder, who then has 45 days to file a patent infringement lawsuit. If the patent holder sues, an automatic 30-month stay of FDA approval for the generic product begins. If the patent holder wins or settles, the generic launch is delayed. If the generic company wins, it gets 180 days of market exclusivity as the first filer.<\/p>\n\n\n\n

For niche branded generic companies, Paragraph IV litigation is both a threat and a strategic tool. The threat is straightforward: if a niche player builds a valuable brand, generic companies will eventually file Paragraph IV challenges against the patents protecting it. Defending against those challenges requires litigation budgets and a patent portfolio robust enough to survive challenge. The strategic opportunity is that a well-timed Paragraph IV challenge against a competitor’s branded product — if successful — can create a first-mover generic opportunity that generates a burst of high-margin revenue during the 180-day exclusivity window.<\/p>\n\n\n\n

Companies like Par Pharmaceutical (now Endo International’s subsidiary), Amneal, and Hikma have built businesses around the intersection of Paragraph IV strategy and niche product selection. They choose products where the patent challenge is likely to succeed, file early to get first-to-file status, and prepare for rapid commercial launch if the challenge succeeds. The litigation is expensive and uncertain, but the financial reward for winning a challenge against a multi-hundred-million-dollar brand can be extraordinary.<\/p>\n\n\n\n

India’s Section 3(d): The Patent System’s Local Character<\/h2>\n\n\n\n

India’s patent law contains a provision unique in global pharmaceutical patent practice: Section 3(d) of the Indian Patents Act, which prohibits granting patents for new forms of known substances unless they demonstrate “significantly enhanced efficacy” compared to the known substance. [10] This provision was specifically designed to prevent “evergreening” — the practice of making minor modifications to existing drugs and obtaining new patents that extend market exclusivity without meaningful therapeutic benefit.<\/p>\n\n\n\n

Section 3(d) has been applied most famously in the Novartis Glivec case, where the Supreme Court of India in 2013 denied a patent for imatinib mesylate (the beta crystalline form) because Novartis could not demonstrate significantly enhanced efficacy over the previously known substance. [11] The ruling had profound commercial consequences: it meant that generic manufacturers in India could produce imatinib at a fraction of the global brand price, making a potentially life-saving cancer treatment accessible to millions of patients who could not afford the innovator price.<\/p>\n\n\n\n

For Indian branded generic companies, Section 3(d) is a double-edged reality. On one hand, it limits the kind of minor reformulation patent strategies that US niche players use effectively. On the other hand, it keeps the field clear for Indian manufacturers to produce generic versions of globally patented drugs at competitive prices, which is the foundation of India’s generic drug industry. A company building an India domestic branded generic strategy does not need to worry much about patent protection for its products because the regulatory and IP environment is designed to facilitate generic access rather than protect reformulation premiums.<\/p>\n\n\n\n

Compulsory Licensing: The Sovereign Wild Card<\/h2>\n\n\n\n

India’s patent law also allows for compulsory licensing — mandatory licensing of a patent to a generic manufacturer without the patent holder’s consent — under specific conditions including non-availability of the patented product in India at a reasonably affordable price. In 2012, India’s Controller of Patents issued its first compulsory license for sorafenib (Bayer’s Nexavar, an oncology drug), requiring Bayer to license the patent to Natco Pharma at a royalty of 6 percent. [12] Natco subsequently sold the drug at a fraction of Bayer’s price.<\/p>\n\n\n\n

The compulsory licensing mechanism is a real business risk for any innovative pharmaceutical company considering India market entry, but it is also a somewhat limited risk in practice: India has issued only one compulsory license in its history, and the political and trade consequences of broad compulsory licensing use would be significant. For Indian branded generic companies, the existence of compulsory licensing is primarily relevant as a competitive context rather than a tool they directly use.<\/p>\n\n\n\n

Biosimilars: The New Frontier for Both Models<\/h1>\n\n\n\n

Biosimilar medicines — biological drugs shown to be highly similar to already-approved reference biologic products — represent a growing and strategically important segment for both the US niche model and the India mass market model, though the business case and competitive dynamics differ substantially between the two contexts.<\/p>\n\n\n\n

India’s Early Biosimilar Advantage<\/h2>\n\n\n\n

India established itself as a biosimilar producer well before the regulatory frameworks in the US and Europe were mature enough to support an approved biosimilar market. Indian companies including Dr. Reddy’s, Cipla, Biocon, and Intas Pharmaceuticals developed and commercialized biosimilar versions of trastuzumab (Herceptin), bevacizumab (Avastin), rituximab (MabThera), insulin analogues, and erythropoietin for the Indian domestic market and for emerging markets in Asia, Latin America, and Africa.<\/p>\n\n\n\n

The commercial logic in India was clear: biologics for cancer and chronic disease were priced in India at $1,000 to $5,000 per treatment course when sold as global brands, accessible only to the wealthiest Indian patients. Indian biosimilars priced at $100 to $500 per treatment course could reach a dramatically larger patient population and still generate commercially attractive margins for manufacturers with efficient production. Biocon’s partnership with Mylan (now Viatris) extended this logic into the US and European markets, building on Biocon’s manufacturing capability and Mylan’s regulatory and commercial infrastructure in those markets.<\/p>\n\n\n\n

US Biosimilar Market Evolution<\/h2>\n\n\n\n

The US biosimilar market has grown more slowly than industry advocates expected when the Biologics Price Competition and Innovation Act (BPCIA) created the approval pathway in 2010. Legal battles between biosimilar manufacturers and originator biologics companies, complex patent litigation, and PBM formulary practices that favored originators with large rebates all contributed to delayed biosimilar adoption. But the landscape shifted materially in 2023 when multiple biosimilars of Humira (adalimumab) entered the US market, including products from AbbVie’s own biosimilar portfolio, Amgen, Pfizer, Sandoz, and Boehringer Ingelheim.<\/p>\n\n\n\n

For Indian companies pursuing the US market, the biosimilar pathway offers a different risk-reward profile from either branded generic niche strategy or commodity generic ANDA. Biosimilar development is more expensive than generic development — requiring analytical comparability studies, potentially a clinical pharmacology study, and sometimes an efficacy study — but less expensive than a novel biologic. The commercial opportunity in the US is substantial: Humida generated approximately $21 billion in global revenues in 2022, [13] and even a modest biosimilar share of that market represents hundreds of millions of dollars. But the commercial challenge of convincing US physicians, hospitals, and PBMs to switch patients from a well-established biologic to a biosimilar requires investment and relationships that many Indian companies are still building.<\/p>\n\n\n\n

Regulatory Comparison: FDA vs. CDSCO<\/h1>\n\n\n\n

The regulatory environment is not just a compliance requirement for pharmaceutical companies — it shapes the entire strategic landscape of each market.<\/p>\n\n\n\n

FDA: The Gatekeeper of Value<\/h2>\n\n\n\n

The FDA’s New Drug Application process for 505(b)(2) products typically takes 10 to 24 months from submission to approval for a standard review, and 6 months for Priority Review designation. The total cost of FDA approval for a 505(b)(2) product — including the PDUFA user fee (approximately $3.4 million for fiscal year 2024 [14]), the clinical development costs, and the regulatory affairs labor required to prepare and respond to a complete submission — commonly runs to $15 million to $50 million for a product with a meaningful clinical differentiation story.<\/p>\n\n\n\n

That cost is the price of entry to a market where pricing power exists. The FDA approval also confers credibility: a product that has cleared FDA review has met standards for safety, efficacy, and quality that create market differentiation from unauthorized imports or unapproved alternatives. In the US context, FDA approval is both a regulatory requirement and a marketing asset.<\/p>\n\n\n\n

CDSCO and the Approval Dynamics in India<\/h2>\n\n\n\n

India’s CDSCO has historically been understaffed and under-resourced relative to the volume of applications it receives. The domestic branded generic approval process for a product that is already approved elsewhere — through Schedule Y of the Drugs and Cosmetics Act — can be completed in 12 to 18 months, though delays are common. The total regulatory cost for a domestic Indian branded generic product, including fees, dossier preparation, and regulatory labor, is a fraction of FDA costs.<\/p>\n\n\n\n

The lower regulatory bar cuts both ways. It allows smaller Indian companies to launch branded generics with limited evidence of differentiation from existing products, creating a highly fragmented market in many therapeutic categories. It also means that the quality signals available to Indian physicians when choosing between branded generics are weaker than the quality signals that FDA approval provides in the US. This fragmentation is both a competitive challenge and a business opportunity: companies that can demonstrate genuine quality consistency and supply reliability in a fragmented market build trust that translates into lasting brand premiums.<\/p>\n\n\n\n

Data Exclusivity: The Asymmetry<\/h2>\n\n\n\n

US new drug applications carry data exclusivity periods that prevent the FDA from relying on the original applicant’s safety and efficacy data for a defined period — typically five years for new chemical entities and three years for new clinical studies supporting a changed condition of approval. Orphan drug designations carry seven years of market exclusivity. These exclusivity periods are additional to and independent of patent protection, and they create a floor of competitive protection that does not depend on maintaining a valid patent.<\/p>\n\n\n\n

India does not offer equivalent pharmaceutical data exclusivity. The regulatory framework does not prevent Indian manufacturers from relying on published clinical data to support their own applications in the way that US data exclusivity does. This is another reason why the competitive moat in Indian branded generics is built on brand equity, physician relationships, and supply reliability rather than regulatory protection.<\/p>\n\n\n\n

Digital Transformation: Different Disruptions<\/h1>\n\n\n\n

The digital transformation of healthcare is affecting both models, but in different ways and at different speeds.<\/p>\n\n\n\n

E-Pharmacies Disrupting Indian Branded Generics<\/h2>\n\n\n\n

The growth of online pharmaceutical retail in India — platforms like Tata 1mg, PharmEasy, and Apollo Pharmacy’s digital channel — is creating genuine disruption for the traditional branded generic commercial model. When a patient can order any branded generic online and receive it at home, the physician’s prescription still drives the initial product choice, but the pharmacy substitution dynamics change. Online pharmacies are more likely to suggest lower-cost alternatives to prescribed brands than physical pharmacists who have relationships with sales representatives of premium brands.<\/p>\n\n\n\n

The penetration of e-pharmacies in India accelerated significantly during COVID-19 and has sustained that growth trajectory. IQVIA estimates that online pharmacy represents approximately 8 to 10 percent of India’s retail pharmaceutical market by value in 2023, up from less than 1 percent in 2018. [15] For Indian branded generic companies, this shift requires investment in digital marketing, patient engagement apps, and loyalty programs that were not part of the traditional commercial model.<\/p>\n\n\n\n

Digital in the US Niche Context<\/h2>\n\n\n\n

For US niche branded generic companies, digital transformation is more about patient support programs, adherence monitoring, and hub services than about retail channel disruption. Specialty pharmacies operating in the US already deliver most niche branded products direct to patients, and the integration of digital patient management tools with specialty pharmacy operations has become a competitive differentiator. Companies that can demonstrate better patient adherence rates — through digital reminders, telehealth check-ins, or continuous glucose monitoring integrations for diabetes drugs — can make a health-economic argument to payers that their product generates better real-world outcomes than alternatives, supporting formulary placement and price premiums.<\/p>\n\n\n\n

Artificial intelligence and real-world evidence analysis are becoming important tools for both models. In the US, AI-driven analysis of claims data, electronic health records, and specialty pharmacy dispensing data allows niche companies to identify under-treated patient populations, optimize targeting for their sales forces, and build pharmacoeconomic models that support payer negotiations. In India, AI is beginning to be used by larger companies to optimize field force deployment, analyze prescription patterns, and identify which physicians are the most efficient targets for representative visits.<\/p>\n\n\n\n

The Investor View: Valuation, Returns, and M&A<\/h1>\n\n\n\n

For investors, the two models present different financial profiles and different sources of uncertainty. Understanding which model generates more durable returns — and what can go wrong with each — is essential context for pharmaceutical sector investment analysis.<\/p>\n\n\n\n

Valuation Multiples<\/h2>\n\n\n\n

US specialty pharmaceutical companies with defensible niche branded positions typically trade at higher enterprise value multiples than their Indian branded generic counterparts. A US specialty pharma with a portfolio of orphan-designated products protected by layered IP might trade at 8 to 14 times revenue or 15 to 25 times EBITDA if the portfolio is well-defended and pipeline optionality is real. By contrast, large Indian branded generic companies with strong domestic franchises trade at 4 to 8 times revenue and 20 to 35 times earnings — high PE multiples but lower revenue multiples, reflecting both the growth potential of Indian domestic healthcare spending and the capital-efficiency of the branded generic model in that market.<\/p>\n\n\n\n

Sun Pharma trades at a premium to other Indian pharmaceutical companies partly because its US specialty ambitions and its strong domestic branded franchise create a dual-upside story that investors are willing to pay for. Dr. Reddy’s, with its more complex US generics-focused strategy, trades at a discount to Sun on most valuation metrics. Torrent Pharmaceuticals, which is almost purely focused on India and select European markets, trades on domestic healthcare growth expectations rather than US specialty optionality.<\/p>\n\n\n\n

ROI Durability: Which Model Holds Up?<\/h2>\n\n\n\n

The durability of returns differs between the two models in ways that matter for long-term investors. In the US niche market, the primary risk to return durability is patent challenge: a successful Paragraph IV challenge can destroy a niche brand’s pricing power overnight if the IP is not layered robustly. The second risk is payer pushback: a payer that decides a niche drug is not sufficiently differentiated to justify its price can demand significant rebates or move the product to a non-preferred formulary tier, eroding revenue. Both risks are manageable with proper IP and commercial strategy but are always present.<\/p>\n\n\n\n

In India, the primary risk to return durability is field force degradation: if a company’s medical representatives lose their competitive edge or if a competitor builds a more effective field presence in a key therapeutic segment, brand market share can erode gradually and persistently. The second risk is price control expansion: if the NLEM is expanded to cover therapeutic categories where a company has premium branded positions, the regulatory stroke of a pen can compress margins across an entire segment. Both risks require ongoing investment and management attention but are not the sudden catastrophic events that patent challenge or payer pushback in the US can represent.<\/p>\n\n\n\n

M&A Activity and Strategic Signaling<\/h2>\n\n\n\n

The M&A activity in both segments tells a story about where capital is being allocated and what buyers believe about long-term value. In the US specialty pharmaceutical space, large transactions in recent years have included AstraZeneca’s $27.8 billion acquisition of Horizon Therapeutics, Pfizer’s $5.4 billion acquisition of Arena Pharmaceuticals (rare inflammatory diseases), and Johnson & Johnson’s ongoing interest in specialty pharma bolt-ons. These transactions reflect large pharmaceutical company belief that branded specialty positions are the most defensible and most valuable assets in the post-patent-cliff environment.<\/p>\n\n\n\n

In India, significant M&A has included Abbott’s historic Piramal Healthcare deal, various consolidation moves among second-tier Indian companies, and international private equity interest in the Indian pharmaceutical distribution and branded generic sectors. The BPEA EQT acquisition of Encube Ethicals and the Carlyle investment in SeQuent Scientific reflect private equity recognition that Indian pharmaceutical manufacturing and branded generic assets offer attractive risk-adjusted returns at the right entry price.<\/p>\n\n\n\n

The Convergence Play: Building Both Models Simultaneously<\/h1>\n\n\n\n

The most ambitious pharmaceutical companies are not choosing between the US niche model and the India mass market model — they are trying to build both. Whether this is wise strategic diversification or costly distraction depends on the company, its financial resources, and whether it has genuinely differentiated capabilities that create synergies between the two models.<\/p>\n\n\n\n

Sun Pharma’s Dual Track<\/h2>\n\n\n\n

Sun Pharmaceutical Industries represents the most advanced example of a company genuinely pursuing both models simultaneously. Sun’s domestic India franchise is the country’s largest, built over decades of brand investment, field force development, and therapeutic category leadership. Sun’s US specialty ambitions are expressed through specialty products like ilumya, its branded dermatology portfolio inherited from acquisitions, and its specialty ophthalmology pipeline. The company’s US generic business provides the manufacturing and regulatory infrastructure that supports both the Indian domestic operation and the US specialty pipeline.<\/p>\n\n\n\n

The question for Sun is whether the two models reinforce each other or compete for management attention and capital. At the operating level, the scientific capabilities that Sun develops in dermatology for the Indian market — understanding skin biology, physician relationships with dermatologists, formulation chemistry — do create some synergies with its US dermatology specialty ambitions. The manufacturing discipline and cost efficiency that drives Indian domestic profitability supports competitive US generic operations. But the commercial skills required for PBM negotiation, specialty pharmacy hub management, and FDA regulatory strategy in the US are genuinely different from the field force management and CDSCO navigation skills that drive Indian domestic success. Building both simultaneously requires either a larger management team or accepting that neither model receives the full strategic focus it deserves.<\/p>\n\n\n\n

Lupin’s Bifurcated Strategy<\/h2>\n\n\n\n

Lupin Limited operates a large US generic and specialty business alongside a strong Indian domestic branded generic franchise. In the US, Lupin has pursued a complex generics strategy — focusing on inhalation products, hormonal contraceptives, and controlled substances — that requires specialized manufacturing capability and regulatory expertise. In India, Lupin’s domestic business is strong in cardiovascular, anti-infectives, and respiratory, with particular physician recognition in the tuberculosis treatment space inherited from the company’s historical focus on that therapeutic area.<\/p>\n\n\n\n

Lupin’s experience in the US has been mixed. Its inhalation program has faced regulatory delays and quality-related setbacks. Its US business profitability has been pressured by generic price erosion and manufacturing compliance costs. But the Indian domestic business has remained consistently profitable and growing, providing the financial stability that allows Lupin to continue investing in US complex generics despite the challenges. This is the essential financial argument for running both models: the Indian branded generic business generates reliable cash flows that can fund the higher-risk, higher-reward investments required in the US market.<\/p>\n\n\n\n

When Diversification Helps vs. Hurts<\/h2>\n\n\n\n

The strategic case for combining the two models is most compelling when the India domestic business generates surplus cash that can fund US market investment without compromising domestic competitive spending. It is least compelling when the US market investment diverts management attention and capital from the Indian franchise at a time when domestic competitive pressure is intensifying. The Indian domestic pharmaceutical market is not static — the entry of well-funded competitors, the growth of e-pharmacy substitution, and the expansion of price controls all create ongoing competitive threats that require sustained investment to defend against.<\/p>\n\n\n\n

Companies that have tried to run both models on insufficient capital — or that believed their US business could subsidize the Indian domestic business during a rough patch, or vice versa — have typically found that neither model performs at full potential. The discipline of strategic clarity — knowing what your primary model is and where your resources go in a capital allocation crunch — separates pharmaceutical companies that build lasting value from those that accumulate strategic complexity without proportionate competitive advantage.<\/p>\n\n\n\n

The Emerging Markets Bridge<\/h2>\n\n\n\n

One synthetic opportunity that bridges the two models is the emerging markets pharmaceutical business, which combines elements of both. Markets like Brazil, Mexico, Russia, Southeast Asia, and parts of Africa and the Middle East have branded generic market structures that resemble India’s in terms of physician-driven prescribing, price sensitivity, and field force importance, but they also offer some degree of regulatory data exclusivity and IP protection that creates modest barriers to generic substitution. Companies like Sanofi’s Emerging Markets division, Abbott’s Established Pharmaceuticals Division, and Mylan’s (now Viatris) Emerging Markets segment have built businesses that leverage branded generic commercial skills developed in India and apply them across a broader geographic footprint.<\/p>\n\n\n\n

The emerging markets bridge is particularly attractive for Indian companies that have already built the operational capabilities — formulation science, cost-efficient manufacturing, field force management — that the mass market branded generic model requires. Expanding from India into similar markets in Africa, Southeast Asia, and Latin America uses existing capabilities without requiring the fundamental commercial transformation that US specialty pharmaceutical competition demands.<\/p>\n\n\n\n

The Patent Intelligence Advantage<\/h1>\n\n\n\n

Regardless of which model a pharmaceutical company pursues, systematic patent intelligence has become a non-negotiable operational requirement. The competitive clock in pharmaceutical markets is set by patent expiration dates, regulatory exclusivity periods, and the outcomes of patent litigation. Companies that understand this clock better than their competitors make better business development decisions, avoid investing in assets that are closer to generic competition than they appear, and identify opportunities that others miss.<\/p>\n\n\n\n

Using DrugPatentWatch in Practice<\/h2>\n\n\n\n

DrugPatentWatch is one of the essential intelligence resources for pharmaceutical professionals who need to understand the patent and regulatory exclusivity landscape for specific products. The platform maintains comprehensive data on FDA Orange Book patent listings, patent expiration dates, Paragraph IV certification history, authorized generic agreements, and first-to-file exclusivity windows. For a business development team evaluating a potential acquisition of a US niche branded generic product, a DrugPatentWatch analysis is typically one of the first steps in due diligence.<\/p>\n\n\n\n

The practical applications span both models. For a US niche player, DrugPatentWatch helps identify: which Orange Book patents are vulnerable to Paragraph IV challenge based on prior art or obviousness arguments, how many companies have already filed ANDAs against a target branded product, whether authorized generic agreements are in place that would limit the profitability of a first-filer generic launch, and what the complete exclusivity timeline looks like for a product being considered for acquisition or partnership.<\/p>\n\n\n\n

For an Indian company assessing its US entry strategy, DrugPatentWatch provides the patent landscape intelligence needed to understand which products have clear paths to generic entry (no valid Orange Book patents, or patents already successfully challenged), which products have complex layered IP that would require expensive litigation to clear, and which categories are on the verge of patent cliff transitions that create commercial opportunity windows. The platform’s historical data on Paragraph IV litigation outcomes also provides statistical context on the success rates of different types of patent challenges, informing the risk assessment for any given IP challenge strategy.<\/p>\n\n\n\n

More broadly, the combination of DrugPatentWatch’s patent data with commercial prescription data from sources like IQVIA and Symphony Health, financial data from public filings, and regulatory history from FDA.gov creates the complete intelligence picture that sophisticated pharmaceutical business development requires. The analysts and executives who integrate these data sources systematically are better positioned than those who rely on fragmented, ad-hoc intelligence gathering.<\/p>\n\n\n\n

Competitive Intelligence for Indian Domestic Strategy<\/h2>\n\n\n\n

In the Indian context, patent intelligence serves different purposes. Indian patent law, shaped by Section 3(d) and compulsory licensing provisions, creates a landscape where global pharmaceutical patents often do not restrict generic production in India. But Indian domestic patents — for formulations, delivery systems, and process innovations — do exist and create competitive intelligence requirements for companies monitoring the activities of their domestic competitors.<\/p>\n\n\n\n

Indian branded generic companies monitor their competitors’ patent filings to understand which therapeutic areas they are prioritizing, which formulation technologies they are investing in, and what their innovation pipelines look like. A competitor filing multiple patents around a novel extended-release formulation of an off-patent cardiovascular drug is signaling a brand launch in that therapeutic area, and that intelligence is actionable: it allows the monitoring company to decide whether to pre-empt with their own launch, to respond with a competitive product, or to identify differentiated positioning in an adjacent segment.<\/p>\n\n\n\n

Looking Forward: Where the Models Go From Here<\/h1>\n\n\n\n

Both models are under pressure from forces that will reshape their economics over the next decade, and the companies that anticipate those pressures correctly will outperform those that do not.<\/p>\n\n\n\n

The US Niche Model Under Pressure<\/h2>\n\n\n\n

The Inflation Reduction Act’s drug pricing negotiation provisions represent the most significant structural change to US pharmaceutical pricing in decades. The Medicare Drug Price Negotiation program, which allows CMS to negotiate prices for a defined number of high-expenditure drugs each year, creates new uncertainty about the long-term price trajectory for branded specialty pharmaceuticals. [16] While the initial focus has been on drugs with large Medicare expenditure — mostly blockbuster biologics — the program’s expansion over time will create pricing pressure in segments where niche branded generic companies had previously expected stable pricing power.<\/p>\n\n\n\n

PBM consolidation is a second pressure point. As the largest PBMs become part of integrated healthcare conglomerates with their own specialty pharmacy operations, their leverage in formulary negotiations increases. A niche branded generic with a patient population measured in tens of thousands is not a market-moving negotiation for the largest PBMs, which may simply exclude it from formulary coverage without extended negotiation. Companies building US niche positions must increasingly plan for payer access challenges as part of their commercial launch assumptions.<\/p>\n\n\n\n

India’s Mass Market Evolution<\/h2>\n\n\n\n

India’s branded generic market faces its own structural evolution. The government’s Jan Aushadhi Pradhan Mantri (PMBJP) program, which operates more than 10,000 generic drug stores across India selling drugs at prices 50 to 90 percent below branded equivalents, is a deliberate public health intervention designed to reduce the premium that branded generics command in the Indian market. [17] The program’s expansion has been gradual, but its existence represents a sustained policy push toward unbranded generic substitution that could erode the value of physician-driven brand preferences over time.<\/p>\n\n\n\n

Digital health adoption, telemedicine growth, and increased patient health literacy in India are also gradually shifting the balance of power in the physician-patient-pharmacist triangle that sustains branded generic premiums. As patients become more able to understand what they are taking and why, and as online resources provide pricing transparency that was previously unavailable, the information asymmetry that supported premium branded generic pricing in India will narrow. This does not mean the branded generic model will collapse — physician influence in Indian prescribing remains powerful — but it means the premium that brands command will need to be justified by genuine quality, supply reliability, and clinical evidence rather than simply by familiarity and field force coverage.<\/p>\n\n\n\n

The Innovation Imperative for Both Models<\/h2>\n\n\n\n

Both models, at their best, are pointing toward more genuine innovation. US niche players that built businesses on minor reformulations and price increases are being pushed by payer pressure to demonstrate real clinical value. Indian branded generic companies that built businesses on field force intensity and physician relationships are being pushed by market evolution to invest in genuine formulation differentiation, patient support, and evidence of real-world outcomes. The companies that treat this pressure as an opportunity to build more defensible franchises will prosper. Those that resist it and try to defend legacy positions through lobbying, legal delay, and financial engineering will find their models eroding.<\/p>\n\n\n\n

Key Takeaways<\/h1>\n\n\n\n

The US niche branded generic model and India’s mass market model represent genuinely different theories of pharmaceutical value creation, not geographic variations on the same strategy. Understanding which model fits a company’s capabilities, capital base, and risk tolerance is a prerequisite for rational strategic planning.<\/p>\n\n\n\n

    \n
  • The US niche model requires regulatory investment (505(b)(2) or orphan designation), layered IP strategy, specialty commercial infrastructure, and PBM access expertise. The reward is pricing power that generates extraordinary margins on modest patient volumes.<\/li>\n\n\n\n
  • India’s mass market model requires field force scale, brand investment over years or decades, manufacturing cost discipline, and regulatory navigation skill with CDSCO. The reward is reliable volume-driven cash flows from one of the world’s fastest-growing pharmaceutical markets.<\/li>\n\n\n\n
  • Patent intelligence is critical to both models but serves different functions: in the US, it maps the exclusivity timeline that determines when generic competition arrives; in India, it tracks competitive signals about rivals’ product development directions.<\/li>\n\n\n\n
  • Indian companies entering the US niche market face a specific set of challenges — manufacturing quality compliance, payer access complexity, specialty commercial infrastructure costs — that are materially different from the challenges they have already solved in their domestic market.<\/li>\n\n\n\n
  • Digital disruption and healthcare policy changes are applying different pressures to each model simultaneously: payer pressure and IRA drug pricing in the US, e-pharmacy growth and Jan Aushadhi generic substitution in India.<\/li>\n\n\n\n
  • The convergence play — running both models simultaneously — is financially logical only when India domestic cash flows are robust enough to fund US investment without compromising domestic competitive positioning.<\/li>\n\n\n\n
  • Platforms like DrugPatentWatch provide the patent landscape intelligence that is foundational to business development decisions in both models, enabling teams to assess exclusivity timelines, identify IP risks, and map competitive entry opportunities.<\/li>\n<\/ul>\n\n\n\n

    FAQ: US Niche vs. India Mass Market Branded Generics<\/h1>\n\n\n\n

    1. Can a mid-size Indian pharmaceutical company realistically compete in US niche branded generics without a prior US commercial infrastructure?<\/h2>\n\n\n\n

    Realistically, no — not on a standalone basis. Building a US specialty commercial operation from scratch requires between $50 million and $150 million in upfront investment for a credible specialty sales force, hub services, patient support programs, and PBM access infrastructure. Most mid-size Indian companies do not have this capital to deploy in the US without compromising their Indian domestic operations. The practical path for Indian companies of this size is through partnership: co-promotion agreements with US specialty pharma companies, licensing of products to US-based commercial partners, or acquisition of a small but established US specialty company whose infrastructure can be leveraged for new product launches. Companies that have tried to build US specialty commercial infrastructure organically without this base have generally found the cost-to-revenue ratio unworkable in the first three to five years.<\/p>\n\n\n\n

    2. How does the Drug Price Control Order (DPCO) specifically affect the ROI model for Indian branded generics, and which therapeutic categories face the greatest margin pressure?<\/h2>\n\n\n\n

    The DPCO compresses margins in the National List of Essential Medicines (NLEM) categories by setting ceiling prices below which manufacturers must sell. The categories facing the greatest margin pressure are anti-infectives (particularly oral antibiotics like amoxicillin, azithromycin, and metronidazole), cardiovascular first-line agents (atenolol, amlodipine, enalapril), and basic gastrointestinal products. In these categories, gross margins for manufacturers typically run 35 to 45 percent, compared to 55 to 70 percent for non-NLEM specialty products. The ROI model in NLEM categories therefore depends almost entirely on volume and manufacturing efficiency — companies that cannot produce at the lowest cost in the industry cannot generate acceptable returns in these segments. Non-NLEM categories like branded dermatology, specialty CNS, and lifestyle drugs offer substantially better margin profiles and represent where most Indian branded generic companies focus their brand-building investment.<\/p>\n\n\n\n

    3. What does a robust layered IP strategy look like for a US 505(b)(2) product, and what are the most common mistakes companies make in constructing it?<\/h2>\n\n\n\n

    A robust layered IP strategy for a 505(b)(2) product typically includes a composition of matter patent covering the specific formulation (polymer matrix, particle size, drug-excipient interaction), a method of treatment patent covering the specific clinical indication and dosing regimen, a manufacturing process patent covering any novel production steps, and potentially a dosage form patent for the specific physical presentation. The most common mistakes are: first, relying on a single patent or two patents with similar expiration dates that create a clean cliff rather than a graduated exclusivity wall; second, failing to list all relevant patents in the FDA Orange Book, which is required within 30 days of approval; third, using overly broad claim language that is easier to invalidate through prior art challenge; and fourth, neglecting the patent after launch, failing to add continuation patents that cover the product as commercial knowledge about its clinical performance accumulates. Patent attorneys specializing in pharmaceutical IP use DrugPatentWatch and similar platforms to benchmark patent portfolio structures against industry best practices for products of similar commercial scale.<\/p>\n\n\n\n

    4. Why have biosimilars struggled commercially in the US despite significant investment, and what structural changes might accelerate adoption?<\/h2>\n\n\n\n

    US biosimilar commercial struggles stem from a specific combination of market structure characteristics that do not exist in India or Europe. First, originator biologic companies have offered PBMs substantial rebates tied to formulary exclusivity, meaning PBMs have financial incentives to prefer originators over biosimilars that cannot match those rebates. Second, the specialty pharmacy channel — through which most biologics are dispensed — has historically had financial relationships with originator manufacturers through limited distribution agreements that created structural preferences. Third, physician inertia around switching stable patients from a known biologic to a biosimilar has been reinforced by originator company education programs emphasizing immunogenicity risks that, while real, are significantly less frequent than the marketing implied. Structural changes that could accelerate adoption include CMS mandatory biosimilar step therapy requirements for Medicare Part D, state automatic substitution laws for interchangeable biosimilars (several states have now passed these), and mandatory reporting of the total rebate value that PBMs collect from originator biologics, which would reveal the scale of the financial incentives that have delayed biosimilar adoption.<\/p>\n\n\n\n

    5. For a pharmaceutical investor, which model offers better risk-adjusted returns over a 10-year horizon, and what are the key variables that determine the answer?<\/h2>\n\n\n\n

    Over a 10-year horizon, the India domestic branded generic model has historically offered more consistent risk-adjusted returns, primarily because its cash flow generation is more predictable and less subject to sudden discontinuous shocks. A well-managed Indian domestic branded generic portfolio — diversified across therapeutic categories, protected by brand equity and field force investment — generates steady compounding growth aligned with India’s healthcare spending expansion, which has grown at approximately 10 to 12 percent annually in recent years. The US niche model offers higher potential returns but with substantially higher variance: a single successful niche product with strong IP protection can generate extraordinary returns, but patent challenge, payer access failure, or competitive brand entry can eliminate value rapidly. The key variables for the India model are field force quality maintenance, NLEM expansion risk, and e-pharmacy penetration trajectory. The key variables for the US niche model are IP robustness, payer acceptance, and whether the IRA pricing negotiation program expands to affect the product’s revenue base. For a 10-year horizon, a portfolio approach that captures both models through companies like Sun Pharma offers a risk-adjusted return profile that pure plays in either model cannot match.<\/p>\n\n\n\n

    References<\/h1>\n\n\n\n

    [1] Grand View Research. (2023). Branded Generics Market Size, Share & Trends Analysis Report. https:\/\/www.grandviewresearch.com\/industry-analysis\/branded-generics-market<\/p>\n\n\n\n

    [2] U.S. Food and Drug Administration. (2023). New Drug Application (NDA) Approvals FY2022. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products<\/p>\n\n\n\n

    [3] AstraZeneca. (2022, December 12). AstraZeneca to acquire Horizon Therapeutics for $27.8 billion. AstraZeneca Press Release. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/astrazeneca-to-acquire-horizon-therapeutics.html<\/p>\n\n\n\n

    [4] IQVIA Institute for Human Data Science. (2022). The Use of Medicines in the U.S.: Spending and Usage Trends and Outlook to 2026. IQVIA. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/the-use-of-medicines-in-the-us-2022<\/p>\n\n\n\n

    [5] IQVIA India. (2024). Indian Pharmaceutical Market Report 2023. IQVIA Institute. https:\/\/www.iqvia.com<\/p>\n\n\n\n

    [6] Organisation of Pharmaceutical Producers of India (OPPI). (2022). OPPI Annual Report and Indian Pharma Industry Statistics. OPPI. https:\/\/www.indiaoppi.com<\/p>\n\n\n\n

    [7] Ministry of Chemicals and Fertilizers, Government of India. (2022). National Pharmaceutical Pricing Authority Annual Report 2021-22. NPPA. https:\/\/www.nppaindia.nic.in<\/p>\n\n\n\n

    [8] Glenmark Pharmaceuticals Limited. (2019). Glenmark to Spin-Off Innovation Business as Ichnos Sciences. Glenmark Press Release. https:\/\/www.glenmarkpharma.com<\/p>\n\n\n\n

    [9] Abbott Laboratories. (2010, September 21). Abbott Completes Acquisition of Piramal Healthcare’s Established Pharmaceuticals Business. Abbott Press Release. https:\/\/www.abbott.com\/corpnewsroom\/strategy-and-strength\/abbott-completes-acquisition-of-piramal-healthcares-business.html<\/p>\n\n\n\n

    [10] Government of India. (2005). The Patents (Amendment) Act, 2005. Section 3(d). Official Gazette of India.<\/p>\n\n\n\n

    [11] Supreme Court of India. (2013). Novartis AG vs. Union of India & Others (Civil Appeal Nos. 2706-2716 of 2013).<\/p>\n\n\n\n

    [12] Office of the Controller General of Patents, Designs and Trade Marks. (2012). Compulsory License Application by Natco Pharma Limited. Patent Office, India.<\/p>\n\n\n\n

    [13] AbbVie Inc. (2023). AbbVie 2022 Annual Report. AbbVie Investor Relations. https:\/\/investors.abbvie.com\/financial-information\/annual-reports<\/p>\n\n\n\n

    [14] U.S. Food and Drug Administration. (2023). Prescription Drug User Fee Amendments (PDUFA): FY2024 Fee Rates. FDA. https:\/\/www.fda.gov\/industry\/fda-user-fee-programs\/prescription-drug-user-fee-amendments<\/p>\n\n\n\n

    [15] IQVIA. (2023). Digital Pharmacy Penetration in India: Market Assessment 2023. IQVIA Institute for Human Data Science.<\/p>\n\n\n\n

    [16] U.S. Centers for Medicare & Medicaid Services. (2023). Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026. CMS. https:\/\/www.cms.gov\/inflation-reduction-act<\/p>\n\n\n\n

    [17] Bureau of Pharma PSUs of India (BPPI). (2023). Pradhan Mantri Bhartiya Janaushadhi Pariyojana Annual Report 2022-23. BPPI, Ministry of Chemicals and Fertilizers. https:\/\/janaushadhi.gov.in<\/p>\n","protected":false},"excerpt":{"rendered":"

    A deep-dive into the economics, IP strategy, and competitive dynamics shaping two divergent paths for branded generic pharmaceutical companies The […]<\/p>\n","protected":false},"author":1,"featured_media":36861,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-36859","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/36859","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=36859"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/36859\/revisions"}],"predecessor-version":[{"id":36862,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/36859\/revisions\/36862"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/36861"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=36859"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=36859"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=36859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}